Characterization of the IgG fractions and clinical data of the patients from whom the IgG was obtained
. | Pt A . | Pt B . | Pt C . | Pt D . | Pt E . | Pt F . |
---|---|---|---|---|---|---|
Diagnosis | PAPS | PAPS | SLE-APS | SLE-APS | PAPS | PAPS |
Arterial thrombosis | + | + | + | + | – | + |
Venous thrombosis | + | + | – | – | + | + |
Fetal loss | – | + | + | – | + | – |
GPL, U | 66 | 72 | 74 | 67 | 141 | 117 |
IgG anti-β2GPI, OD values, 405 nm | 1.67 | 1.25 | 1.38 | 2.91 | 2.02 | 0.9 |
Human C1q binding, OD values, 405 nm | 0.89 | 0.87 | 0.88 | 1.20 | 0.98 | 0.96 |
. | Pt A . | Pt B . | Pt C . | Pt D . | Pt E . | Pt F . |
---|---|---|---|---|---|---|
Diagnosis | PAPS | PAPS | SLE-APS | SLE-APS | PAPS | PAPS |
Arterial thrombosis | + | + | + | + | – | + |
Venous thrombosis | + | + | – | – | + | + |
Fetal loss | – | + | + | – | + | – |
GPL, U | 66 | 72 | 74 | 67 | 141 | 117 |
IgG anti-β2GPI, OD values, 405 nm | 1.67 | 1.25 | 1.38 | 2.91 | 2.02 | 0.9 |
Human C1q binding, OD values, 405 nm | 0.89 | 0.87 | 0.88 | 1.20 | 0.98 | 0.96 |
Pt indicates patient; PAPS, primary APS; SLE-APS, systemic lupus erythematosus–associated APS; GPL, IgG antiphospholipid; OD, optical density.